Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRANDA trial of tozorakimab in symptomatic COPD with prior exacerbations
NL-OMON59130Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tozorakimab in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Feb 2024; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON59130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59130.